Converging goals of treatment of inflammatory bowel disease from clinical trials and practice

Gastroenterology

Volumn 148, Issue 1, 2015, Pages 37-51.e1

  Levesque, Barrett G ^a   Sandborn, William J ^a   Ruel, Joannie ^b   Feagan, Brian G ^c   Sands, Bruce E ^b   Colombel, Jean Frederic ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

CDAI; GREAT; IBD Therapy; Outcome Measure

Indexed keywords

ALGORITHM; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE SEVERITY; DRUG MONITORING; GASTROINTESTINAL ENDOSCOPY; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; LABORATORY TEST; MAYO CLINIC SCORE; MEDICAL RESEARCH; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; REMISSION; REVIEW; ULCERATIVE COLITIS; BIOASSAY; CLINICAL PATHWAY; COLITIS, ULCERATIVE; EVIDENCE BASED MEDICINE; PATIENT CARE PLANNING; PREDICTIVE VALUE; SELF REPORT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ALGORITHMS; CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; CRITICAL PATHWAYS; CROHN DISEASE; ENDOSCOPY, GASTROINTESTINAL; ENDPOINT DETERMINATION; EVIDENCE-BASED MEDICINE; HUMANS; PATIENT CARE PLANNING; PREDICTIVE VALUE OF TESTS; REMISSION INDUCTION; SELF REPORT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84922890759     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.08.003     Document Type: Review

References (139)

1. I. Ordas, L. Eckmann, and M. Talamini Ulcerative colitis Lancet 380 2012 1606 1619
2. D.C. Baumgart, and W.J. Sandborn Crohn's disease Lancet 380 2012 1590 1605
3. D.H. Bruining, and W.J. Sandborn Do not assume symptoms indicate failure of anti-tumor necrosis factor therapy in Crohn's disease Clin Gastroenterol Hepatol 9 2011 395 399
4. C. Cellier, T. Sahmoud, and E. Froguel Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives Gut 35 1994 231 235
5. B. Kirshner, and G. Guyatt A methodological framework for assessing health indices J Chronic Dis 38 1985 27 36
6. W.J. Sandborn, B.G. Feagan, and S.B. Hanauer A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease Gastroenterology 122 2002 512 530
7. G. D'Haens, W.J. Sandborn, and B.G. Feagan A review of activity indices and efficacy endponts for clinical trials of medical therapy in adults with ulcerative colitis Gastroenterology 132 2007 763 786
8. US Food and Drug Administration. US Food and Drug Administration (FDA) guidance for industry: patient-reported outcome measures use in medical product development to support labeling claims. 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf.
9. US Food and Drug Administration. Gastroenterology regulatory endpoints and the advancement of therapeutics (GREAT II) workshop; October 21-22, 2013; Bethesda, MD.
10. K.L. Todd III, D. Wright VANISH-2 Investigator Group The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence Phlebology 29 2014 608 618
11. R.A. Mesa, J. Gotlib, and V. Gupta Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial J Clin Oncol 31 2013 1285 1292
12. E. Keystone, D. Heijde, and D. Mason Jr. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Arthritis Rheum 58 2008 3319 3329
13. K.W. Schroeder, W.J. Tremaine, and D.M. Ilstrup Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study N Engl J Med 317 1987 1625 1629
14. G.R. Lichtenstein, S.B. Hanauer, and W.J. Sandborn Management of Crohn's disease in adults Am J Gastroenterol 104 2009 465 483
15. M.K. Vester-Andersen, M.V. Prosberg, and T. Jess Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy Am J Gastroenterol 109 2014 705 714
16. E. Langholz, P. Munkholm, and M. Davidsen Course of ulcerative colitis: analysis of changes in disease activity over years Gastroenterology 107 1994 3 11
17. C.E. Leijonmarck, P.G. Persson, and G. Hellers Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study Gut 31 1990 329 333
18. C. Hendriksen, S. Kreiner, and V. Binder Long term prognosis in ulcerative colitis - based on results from a regional patient group from the county of Copenhagen Gut 26 1985 158 163
19. O. Hoie, F.L. Wolters, and L. Riis Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years Gastroenterology 132 2007 507 515
20. T. Jess, L. Riis, and I. Vind Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark Inflamm Bowel Dis 13 2007 481 489
21. W.A. Faubion Jr., E.V. Loftus Jr., and W.S. Harmsen The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study Gastroenterology 121 2001 255 260
22. D. Turner, C.M. Walsh, and A.H. Steinhart Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression Clin Gastroenterol Hepatol 5 2007 103 110
23. L. Peyrin-Biroulet, E.V. Loftus Jr., and J.F. Colombel The natural history of adult Crohn's disease in population-based cohorts Am J Gastroenterol 105 2010 289 297
24. I.C. Solberg, M.H. Vatn, and O. Hoie Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study Clin Gastroenterol Hepatol 5 2007 1430 1438
25. E. Domenech, Y. Zabana, and E. Garcia-Planella Clinical outcome of newly diagnosed Crohn's disease: a comparative, retrospective study before and after infliximab availability Aliment Pharmacol Ther 31 2010 233 239
26. R.R. Cannom, A.M. Kaiser, and G.T. Ault Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates? Am Surg 75 2009 976 980
27. D.W. Jones, and S.R. Finlayson Trends in surgery for Crohn's disease in the era of infliximab Ann Surg 252 2010 307 312
28. S.C. Truelove, and L.J. Witts Cortisone in ulcerative colitis; final report on a therapeutic trial Br Med J 2 1955 1041 1048
29. P. Rutgeerts, K. Geboes, and G. Vantrappen Predictability of the postoperative course of Crohn's disease Gastroenterology 99 1990 956 963
30. J.H. Baron, A.M. Connell, and J.E. Lennard-Jones Variation between observers in describing mucosal appearances in proctocolitis BMJ 1 1964 89 92
31. B.G. Feagan, G.R. Greenberg, and G. Wild Treatment of ulcerative colitis with a humanized antibody to the a4b7 integrin N Engl J Med 352 2005 2499 2507
32. P. Rutgeerts, W.J. Sandborn, and B.G. Feagan Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 353 2005 2462 2476
33. W.J. Sandborn, B.G. Feagan, and C. Marano Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis Gastroenterology 146 2014 85 95 quiz e14-e15
34. W.J. Sandborn, G. van Assche, and W. Reinisch Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis Gastroenterology 142 2012 257 265 e1-3
35. W.J. Sandborn, S. Travis, and L. Moro Once-daily budesonide MMX(R) extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study Gastroenterology 143 2012 1218 1226 e1-2
36. P. Rutgeerts, J.F. Colombel, and W. Reinisch Infliximab induces and maintains mucosal healing in patients with active ulcerative colitis: the ACT trial experience Gut 54 suppl VII 2005 A58
37. J.D. Lewis, S. Chuai, and L. Nessel Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis Inflamm Bowel Dis 14 2008 1660 1666
38. W.R. Best, J.M. Becktel, and J.W. Singleton Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study Gastroenterology 70 1976 439 444
39. R.W. Summers, D.M. Switz, and J.T. Sessions Jr. National Cooperative Crohn's Disease Study: results of drug treatment Gastroenterology 77 1979 847 869
40. S. Candy, J. Wright, and M. Gerber A controlled double blind study of azathioprine in the management of Crohn's disease Gut 37 1995 674 678
41. B.G. Feagan, J. Rochon, and R.N. Fedorak Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators N Engl J Med 332 1995 292 297
42. G.R. Greenberg, B.G. Feagan, and F. Martin Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group N Engl J Med 331 1994 836 841
43. S.B. Hanauer, B.G. Feagan, and G.R. Lichtenstein Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet 359 2002 1541 1549
44. J.F. Colombel, W.J. Sandborn, and P. Rutgeerts Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial Gastroenterology 132 2007 56 65
45. W.J. Sandborn, B.G. Feagan, and S. Stoinov Certolizumab pegol for the treatment of Crohn's disease N Engl J Med 357 2007 228 238
46. W.J. Sandborn, J.F. Colombel, and R. Enns Natalizumab induction and maintenance therapy for Crohn's disease N Engl J Med 353 2005 1912 1925
47. R.S. Sandler, M.C. Jordan, and L.L. Kupper Development of a Crohn's index for survey research J Clin Epidemiol 41 1988 451 458
48. K.T. Thia, W.J. Sandborn, and J.D. Lewis Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease Am J Gastroenterol 103 2008 3123 3131
49. R.F. Harvey, and J.M. Bradshaw A simple index of Crohn's-disease activity Lancet 1 1980 514
50. S. Vermeire, S. Schreiber, and W.J. Sandborn Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity Clin Gastroenterol Hepatol 8 2010 357 363
51. J. Jones, E.V. Loftus Jr., and R. Panaccione Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease Clin Gastroenterol Hepatol 6 2008 1218 1224
52. C. Lahiff, P. Safaie, and A. Awais The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome Aliment Pharmacol Ther 37 2013 786 794
53. J.R. Korzenik, B.K. Dieckgraefe, and J.F. Valentine Sargramostim for active Crohn's disease N Engl J Med 352 2005 2193 2201
54. J.F. Colombel, W.J. Sandborn, and W. Reinisch Infliximab, azathioprine, or combination therapy for Crohn's disease N Engl J Med 362 2010 1383 1395
55. J.Y. Mary, and R. Modigliani Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID) Gut 30 1989 983 989
56. J.Y. Mary, M. Lémann, and J.F. Colombel Endoscopic remission and response in Crohn's disease an objective definition using the CDEIS Gut 37(Suppl 1) 2006 A55
57. C.J. van der Woude, P. Stokkers, and A.A. van Bodegraven Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease Inflamm Bowel Dis 16 2010 1708 1716
58. X. Hebuterne, M. Lemann, and Y. Bouhnik Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol Gut 62 2013 201 208
59. P. Rutgeerts, G. Van Assche, and W.J. Sandborn Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial Gastroenterology 142 2012 1102 1111.e2
60. K. Geboes, P. Rutgeerts, and G. Opdenakker Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease Curr Med Res Opin 21 2005 1741 1754
61. G. Bresci, G. Parisi, and S. Banti Long-term therapy with 5-aminosalicylic acid in Crohn's disease: Is it useful? Our four years experience Int J Clin Pharmacol Res 14 1995 133 138
62. J. Bauditz, J. Haemling, and M. Ortner Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease Gut 40 1997 470 474
63. R. Burakoff, C.F. Barish, and D. Riff A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease Inflamm Bowel Dis 12 2006 558 565
64. J.F. Colombel, M. Lemann, and Y. Bouhnik Endoscopic healing of Crohn's ileo-colitis with azathioprine (abstr) Gastroenterology 124 2003 A196 A197
65. G. D'Haens, S. van Deventer, and R. Van Hogezand Anti-TNFa monoclonal antibody (cA2) produces endoscopic healing in patients with treatment-resistant, active Crohn's disease (abstr) Gastroenterology 114 1998 A1108
66. G. D'Haens, S. Van Deventer, and R. Van Hogezand Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial Gastroenterology 116 1999 1029 1034
67. I. Dotan, D. Rachmilewitz, and S. Schreiber A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease Gut 59 2010 760 766
68. M. Duijvestein, A.C.W. Vos, and H. Roelofs Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study Gut 59 2010 1662 1669
69. R.N. Fedorak, A. Gangl, and C.O. Elson Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group Gastroenterology 119 2000 1473 1482
70. J. Florie, K. Horsthuis, and D.W. Hommes Magnetic resonance imaging compared with ileocolonoscopy in evaluating disease severity in Crohn's disease Clin Gastroenterol Hepatol 3 2005 1221 1228
71. C. Gasche, W. Reinisch, and H. Vogelsang Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease Dig Dis Sci 40 1995 800 804
72. C.J. Hawkey Controlled trial of immunoablation and autologous haemopoetic stem cell transplantation in Crohn's disease: interim report on behalf of the ASTIC trialists. A trial from the EBMT Autoimmune Diseases Working Party Bone Marrow Transplant 47 2012 S82
73. D. Hommes, B. Van Den Blink, and T. Plasse Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease Gastroenterology 122 2002 7 14
74. H. Ito, M. Takazoe, and Y. Fukuda A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease Gastroenterology 126 2004 989 996 discussion 947
75. S. Keshav, D.J. Johnson, and P. Bekker (Traficet-EN) in treatment of patients with moderate to severe Crohn's disease Gastroenterology 136 2009 392
76. D. Laharie, A. Reffet, and G. Belleannée Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab Aliment Pharmacol Ther 33 2011 714 721
77. M. Lemann, Y. Bouhnik, and J.F. Colombel Randomized, double-blind, placebo-controlled, multicenter, azathioprine (AZA) withdrawal trial in Crohn's disease (CD) (abstr) Gastroenterology 122 2002 A23
78. M. Lemann, J.Y. Mary, and B. Duclos Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial Gastroenterology 130 2006 1054 1061
79. G.J. Mantzaris, A. Christidou, and M. Sfakianakis Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease Inflamm Bowel Dis 15 2009 375 382
80. R. Modigliani, B. Landi, and T. Nguyen Acute attacks of colonic and ileocolonic Crohn's disease (CICD): is colonoscopic follow-up useful to adjust steroid treatment duration? (abstr) Gastroenterology 98 1990 A193
81. W. Reinisch, D.W. Hommes, and G. Van Assche A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease Gut 55 2006 1138 1144
82. J. Ren, Q. Tao, and X. Wang Efficacy of T2 in active Crohn's disease: a prospective study report Dig Dis Sci 52 2007 1790 1797
83. J. Rimola, I. Ordas, and S. Rodriguez Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity Inflamm Bowel Dis 17 2011 1759 1768
84. P. Rutgeerts, M.C. Allison, and A. Cortot Effects of natalizumab on gut healing in a phase 3 study of active Crohn's disease therapy (ENACT-1) (abstr) Gastroenterology 126 2004 A208
85. P. Rutgeerts, G. Assche, and W.J. Sandborn Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial Gastroenterology 142 2012 1102 1111. e2
86. P. Rutgeerts, R.H. Diamond, and M. Bala Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease Gastrointest Endosc 63 2006 433 442 quiz 464
87. P. Rutgeerts, G. Van Assche, and S. Van Deventer Infliximab maintenance treatment strategy results in mucosal healing in patients with Crohns disease (abstr) Gastroenterology 122 2002 A618
88. J.P. Smith, S.I. Bingaman, and F. Ruggiero Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial Dig Dis Sci 56 2011 2088 2097
89. C.J. van der Woude, P. Stokkers, and A.A. van Bodegraven Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease Inflamm Bowel Dis 16 2010 1708 1716
90. M. Daperno, G. D'Haens, and G. Van Assche Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD [see comment] Gastrointest Endosc 60 2004 505 512
91. C.G. af Bjorkesten, U. Nieminen, and U. Turunen Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease Scand J Gastroenterol 47 2012 528 537
92. A.M. Schoepfer, C. Beglinger, and A. Straumann Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI Am J Gastroenterol 105 2010 162 169
93. E. Archavlis, K. Papamichael, and D. Tzivras Adalimumab for patients with Crohn's disease and secondary loss of response or severe allergy to infliximab (abstr) J Crohns Colitis 5 2011 S86
94. F. Baert, L. Moortgat, and G. Van Assche Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease Gastroenterology 138 2010 463 468 quiz e10-e11
95. F. Casellas, M. Barreiro de Acosta, and M. Iglesias Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease Eur J Gastroenterol Hepatol 24 2012 762 769
96. Z. Czegledi, P. Miheller, and T. Molnar Medium term efficacy, mucosal healing and safety of adalimumab therapy in patients with Crohn's disease. National data from Hungary (abstr) Gastroenterology 138 2010 S-699
97. P. Hasselblatt, K. Drognitz, and K. Potthoff Remission of refractory Crohn's disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation Aliment Pharmacol Ther 36 2012 725 735
98. C. Hawkey, M. Allez, and S. Ardizzone Clinical and endocopic improvement following hemopoietic stem cell transplantation in the ASTIC trial (abstr) J Crohns Colitis 7 2013 S4
99. D. Laharie, A. Reffet, and G. Belleannée Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab Am J Gastroenterol 33 2011 714 721
100. E.A. Maser, R. Villela, and M.S. Silverberg Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease Clin Gastroenterol Hepatol 4 2006 1248 1254
101. R. Rismo, T. Olsen, and G. Ciu The effect of adalimumab for induction of endoscopic healing and normalization of mucosal cytokine gene expression in Crohn's disease Scand J Gastroenterol 47 2012 1200 1210
102. G. Van Assche, C. Magdelaine-Beuzelin, and G. D'Haens Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial Gastroenterology 134 2008 1861 1868
103. G. Van Assche, G. Paintaud, and C. Magdelaine Concomitant Immunosuppression does not impact on the outcome of maintenance infliximab therapy in Crohn's disease: final results of the Imid trial (abstr) Gastroenterology 132 2007 A-103
104. M. Ferrante, J.F. Colombel, and W.J. Sandborn Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC Gastroenterology 145 2013 978 986. e5
105. R. Khanna, G. D'Haens, and B.G. Feagan Patient reported outcome measures derived from the Crohn's Disease Activity Index: correlation between PRO2 and PRO3 scores and CDAI-defined clinical threshold (abstr) J Crohns Colitis 8 2014 S135 S136
106. S.P. Travis, D. Schnell, and P. Krzeski Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) Gut 61 2012 535 542
107. S.P. Travis, D. Schnell, and P. Krzeski Reliability and initial validation of the ulcerative colitis endoscopic index of severity Gastroenterology 145 2013 987 995
108. B.G. Feagan, W.J. Sandborn, and G. D'Haens The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis Gastroenterology 145 2013 149 157. e2
109. J.R. Landis, and G.G. Koch The measurement of observer agreement for categorical data Biometrics 33 1977 159 174
110. B.G. Levesque, E.V. Loftus, and R. Panaccione Responsiveness of endoscopic indices in the evaluation of ulcerative colitis (abstr) J Crohns Colitis 8 2014 S124
111. R. Khanna, G. Zou, and G. D'Haens Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease (abstr) J Crohns Colitis 8 2014 S13 S14
112. R. Khanna, G. Zou, and G.R. D'Haens Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease Gastroenterology 146 2014 5 (Suppl 1)S175
113. S.C. Truelove, and W.C.D. Richards Biopsy studies in ulcerative colitis BMJ 4979 1956 1315 1318
114. A. Bitton, M.A. Peppercorn, and D.A. Antonioli Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis Gastroenterology 120 2001 13 20
115. B. Christensen, J. Erlich, and S.B. Hanauer Agreement between deep histological remission and mucosal healing in ulcerative colitis and predictors of each outcome (abstr) Gastroenterology 146 2014 S-172
116. B.I. Korelitz, and S.C. Sommers Differential diagnosis of ulcerative and granulomatous colitis by sigmoidoscopy, rectal biopsy and cell counts of rectal mucosa Am J Gastroenterol 61 1974 460 469
117. B.I. Korelitz, and S.C. Sommers Responses to drug therapy in ulcerative colitis. Evaluation by rectal biopsy and histopathological changes Am J Gastroenterol 64 1975 365 370
118. M.H. Mosli, B.G. Feagan, and W.J. Sandborn Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices Inflamm Bowel Dis 20 2014 564 575
119. M.H. Mosli, B.G. Feagan, and G. Zou Agreement of central readers in the evaluation of histopathological disease activity in ulcerative colitis (abstr) J Crohns Colitis 8 2014 S181 S182
120. G.R. D'Haens, K. Geboes, and M. Peeters Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum Gastroenterology 114 1998 262 267
121. B.V. Naini, and G. Cortina A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease Hum Pathol 43 2012 2187 2196
122. B. Pariente, J. Cosnes, and S. Danese Development of the Crohn's disease digestive damage score, the Lemann score Inflamm Bowel Dis 17 2011 1415 1422
123. J. Rimola, S. Rodriguez, and O. Garcia-Bosch Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease Gut 58 2009 1113 1120
124. M.J. Steward, S. Punwani, and I. Proctor Non-perforating small bowel Crohn's disease assessed by MRI enterography: derivation and histopathological validation of an MR-based activity index Eur J Radiol 81 2012 2080 2088
125. G. Bouguen, B.G. Levesque, and B.G. Feagan Treat to target: a proposed new paradigm for the management of Crohn's disease Clin Gastroenterol Hepatol 2013 Sep 10 [Epub ahead of print]
126. S. Ardizzone, A. Cassinotti, and P. Duca Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis Clin Gastroenterol Hepatol 9 2011 483 489 e3
127. J.F. Colombel, P. Rutgeerts, and W. Reinisch Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis Gastroenterology 141 2011 1194 1201
128. K.F. Froslie, J. Jahnsen, and B.A. Moum Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort Gastroenterology 133 2007 412 422
129. F. Schnitzler, H. Fidder, and M. Ferrante Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort Gut 58 2009 492 500
130. G. D'Haens, F. Baert, and G. van Assche Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial Lancet 371 2008 660 667
131. M. Allez, M. Lemann, and J. Bonnet Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy Am J Gastroenterol 97 2002 947 953
132. N. Vande Casteele, A. Gils, and V. Ballet Randomised controlled trial of drug level versus clinically based dosing of infliximab maintenance therapy in IBD: final results of the TAXIT Study United Eur Gastroenterol J 1(Suppl1) 2013 A1
133. F.S. Velayos, J.G. Kahn, and W.J. Sandborn A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab Clin Gastroenterol Hepatol 11 2013 654 666
134. A randomized evaluation of health costs and resource utilization comparing testing-based therapy to empiric dose intensification for the management of inflammatory bowel disease. http://clinicaltrials.gov/show/NCT01960426.
135. J.F. Lin, J.M. Chen, and J.H. Zuo Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity Inflamm Bowel Dis 20 2014 1407 1415
136. G. Bouguen, B.G. Levesque, and S. Pola Feasibility of endoscopic assessment and treating to target to achieve mucosal healing in ulcerative colitis Inflamm Bowel Dis 20 2014 231 239
137. G. Bouguen, B.G. Levesque, and S. Pola Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn's disease Clin Gastroenterol Hepatol 12 2014 978 985
138. R. Khanna, B.G. Levesque, and B. Bressler Early combined immunosuppression for the management of Crohn's disease: a community-based cluster randomized trial (abstr) J Crohns Colitis 8 2014 S2 S3
139. K. Papamichael, A. Gils, and P.J. Rutgeerts The role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary non response Inflamm Bowel Dis 2014 Sep 12 [Epub ahead of print]